AbbVie Is Closing Its Free Humira Program — Here's What to Do Before July 1
Patient Assistance ProgramsMarch 8, 2026

AbbVie Is Closing Its Free Humira Program — Here's What to Do Before July 1

myAbbVie Assist stops accepting new Humira applications on July 1, 2026. Here's a step-by-step guide for current patients and those who were about to apply — including which biosimilar assistance programs to use instead.

Written by

J

Jacob Elich

Health Consulting & Business Operations

Jacob Elich is the founder of ClariMeds and an MBA-trained business operator with a background in health consulting and dealmaking. He started ClariMeds after watching family members struggle to afford medications they were prescribed but couldn't pay for — and realizing that the manufacturer assistance programs that could have helped them were largely invisible to the people who needed them most. His work focuses on closing that gap.

If you've been relying on myAbbVie Assist to afford Humira — or if you were planning to apply — there's a deadline you need to know about.

AbbVie announced that effective July 1, 2026, myAbbVie Assist will stop accepting new applications for Humira. Patients currently enrolled can remain in the program through their existing eligibility period, but no new enrollments will be accepted after that date.

This is a significant change. myAbbVie Assist has been one of the most widely used patient assistance programs in the country, providing free Humira to qualifying patients who couldn't otherwise afford it. Here's what it means for you and what to do before the deadline.

Why Is AbbVie Closing the Program?

The short answer is market dynamics. Humira's U.S. revenues have dropped sharply — down roughly 58% in the first half of 2025 — as biosimilar competition intensifies. Ten FDA-approved adalimumab biosimilars are now on the market, most priced significantly below Humira's list price.

From AbbVie's perspective, the rationale for maintaining a free-drug program for their most expensive product diminishes when cheaper, clinically equivalent alternatives exist. The business case for myAbbVie Assist was always partly about keeping patients on Humira; with biosimilars taking market share, that calculus has shifted.

That said, the closure creates a real problem for patients who depend on Humira specifically and haven't yet transitioned.

If You're Currently Enrolled in myAbbVie Assist

You don't need to do anything immediately. AbbVie has confirmed that existing enrollees can continue in the program through their current eligibility period. However:

  • Confirm your re-enrollment date. If your eligibility was set to renew after July 1, 2026, contact myAbbVie Assist now to understand whether your renewal will be honored.
  • Call: 1-800-222-6885 (myAbbVie Assist patient line) to confirm the specific terms of your continued coverage.
  • Start evaluating biosimilar alternatives now, even if you're not required to switch yet. See the biosimilar PAP comparison below.

If You Were Planning to Apply

The July 1 deadline means you need to apply before that date if you want to be considered. To apply:

  1. Confirm eligibility: uninsured or underinsured, income typically at or below 400% FPL
  2. Have your prescriber complete the clinical portion of the application
  3. Gather income documentation (tax return, pay stubs, or SSI award letter)
  4. Submit at myabbvieassist.com or by calling 1-800-222-6885

Processing typically takes 2–4 weeks. Apply as early as possible — do not wait until late June.

Biosimilar PAPs: Your Alternatives After July 1

The good news is that most of Humira's biosimilar competitors have their own patient assistance programs, and several are competitive with or better than myAbbVie Assist:

Sandoz (Hyrimoz / Hyrimoz HD) — Sandoz Patient Assistance Program provides free medication to qualifying uninsured/underinsured patients. Income thresholds are similar to Humira's program.

Organon (Hadlima) — Offers a patient assistance program plus free nurse coaching for patients transitioning to the biosimilar.

Boehringer Ingelheim (Cyltezo) — One of the few interchangeable adalimumab biosimilars; has partnered with GoodRx for uninsured and underinsured patients, with a $0 copay option available.

Amgen (Amjevita) — Amgen's patient assistance foundation offers free medication to income-qualifying patients.

Samsung Bioepis (Hadlima / Yuflyma) — Has copay assistance and PAP options for eligible patients.

What About the Humira Complete Savings Card?

The Humira Complete copay card — which reduces costs to as low as $5/month for commercially insured patients — is a separate program from myAbbVie Assist and is not being closed as of this writing. If you're commercially insured and paying a high copay for Humira, that card may still be available to you.

However, its long-term availability is uncertain as AbbVie continues to wind down investment in Humira's commercial support infrastructure. Check humira.com/humira-complete for current availability.

ClariMeds Can Help You Navigate the Transition

Whether you need to get an application in before the July 1 deadline or want help evaluating which biosimilar PAP is the best fit for your situation, ClariMeds checks eligibility across all applicable programs and handles the paperwork.

Check your options — takes about 5 minutes

This article contains financial and program access information only. ClariMeds does not provide medical advice. Confirm current program terms directly with AbbVie or the relevant biosimilar manufacturer, as details change.

Paying too much for your medication?

ClariMeds connects you to free or low-cost medications through manufacturer assistance programs — and handles every step of the application for you.

See If You Qualify — Free
← Back to all articles